ibrexafungerp

Ibrexafungerp is a first-in-class, orally bioavailable triterpenoid antifungal agent used for the treatment of vulvovaginal candidiasis (VVC) and to reduce the risk of recurrent VVC. It acts by noncompetitively inhibiting β-(1,3)-D-glucan synthase, an essential enzyme in fungal cell wall biosynthesis. This mechanism disrupts fungal cell wall integrity, leading to cell lysis and death. Ibrexafungerp is active against a broad range of Candida species—including azole-resistant and echinocandin-resistant strains—as well as some Aspergillus species and other pathogenic fungi. Developed as an alternative to existing antifungals with oral administration advantages, it was approved by the FDA in June 2021 for VVC[4][6][8].

Brand names

Brexafemme

Other names

IBXibrexafungerp